Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

AB Science248 enrolled

Overview

The objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.

Masitinib is a selective tyrosine kinase inhibitor that is thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. The objective of this study is to evaluate the efficacy and safety of masitinib in combination with gemcitabine as compared with single agent gemcitabine in advanced or metastatic epithelial ovarian cancer patients who are refractory to platinum treatment. This is an open-label, randomized, active-controlled, phase 2/3 study. The study's primary efficacy measure will be overall survival. Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal. The study design is a two-stage adaptive design, meaning that it includes a prospectively planned opportunity for modification of one or more specified aspects of the study (for example patient enrollment).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

248

Conditions

Ovarian Cancer

Interventions

MasitinibDRUG

GemcitabineDRUG

PlaceboDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Main inclusion criteria: 1. Female patient, with histologically or cytologically confirmed advanced / metastatic epithelial ovarian cancer (including primary peritoneal and primary fallopian tube cancer), which is either: * First line platinum-refractory ovarian cancer (progression during first-line platinum-based chemotherapy) * First line platinum-resistant ovarian cancer (relapsing within 6 months after the end of first-line chemotherapy); * Candidate to third line of treatment (refractory, resistant, or sensitive to 2nd line platinum-based therapy or patients who progressed after other type of chemotherapy in 2nd line). 2. Patient with adequate organ function per laboratory tests evaluations Main exclusion criteria: 1. Patient intolerant to gemcitabine 2. Patient who has not recovered from any significant treatment toxicities prior to baseline (≥Grade 2) 3. Pregnant or nursing female patient

Locations (6)

Centre hospitalo-universitaire de Beni Messous

Algiers, Algeria

Institut Sainte Catherine

Avignon, France

City Oncology Clinic

Saint Petersburg, Russia

Complejo Hospitalario Universitario de Santiago

Santiago, Spain

Outcomes

Primary Outcomes

Overall survival (OS)

Overall survival is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

Time frame: From day of randomization to death, assessed for a maximum of 60 months

Secondary Outcomes

Overall Progression Free Survival (PFS)

Progression Free Survival (PFS) \[Time Frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months\] Progression Free Survival is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed by CT scan according to RECIST criteria recommendations.

Time frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.